Portfolio
To address AMR and protect the lives of people around the world, PACE is providing funding and support for a portfolio of early-stage projects to help grow the pipeline of high-quality antimicrobial therapeutics and associated diagnostics.
Supporting the best innovations to address the global threat of AMR
We are supporting a diverse portfolio of projects aimed at developing new tests and treatments for bacterial infections with high unmet need. Through a series of funding rounds available to academics and SMEs worldwide, we are selecting, investing in and supporting the most promising projects. We are offering a collaborative approach to project development through access to advisors, mentors, potential project partners and enabling technologies and capabilities. By supporting the projects in this way, we are helping to give them the best chance of success and position them for onward funding, investment and development. More projects will enter the portfolio as the programme progresses. This page highlights the innovators and projects that are currently in the PACE portfolio.
Number of projects supported
PACE funds committed to projects
Number of organisations funded
ArrePath
ArrePath was founded upon the mission to discover new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state-of-the-art technologies and novel strategies.
We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.
Glox Therapeutics
Glox Therapeutics are developing precision antibiotics to combat antimicrobial resistance. Our goal is to create potent, species-specific antibiotics that, unlike conventional antibiotics, do not harm the host microbiome. We are producing engineered bacteriocins from our proprietary platform technologies to target Gram-negative pathogens.
University of Sheffield
The University of Sheffield’s mission is to deliver life-enhancing research, innovation and education that not only transforms the lives of our graduates, but shapes the world we live in. Our diverse community is made up of 30,000 students from 150 countries, 8,000 staff, including 1,500 of the world’s leading academics and over 300,000 alumni in 205 countries. Our research-led teaching inspire, enthuse and challenge a diverse community of outstanding students. Our graduates will be equipped to stand out as confident global citizens guided by strong values, ethics and standards, able to make meaningful contributions to society.
Our research and innovation will produce the highest quality outputs to drive intellectual advances and address global challenges. The University of Sheffield is a member of the Russell Group and is ranked within the Top 100 universities in the Times Higher Education World University Rankings 2025.
Xiretsa
Xiretsa is a spinout from UC Santa Barbara developing novel membrane-remodelling small molecule antibiotics called Anti-infective Conjugated Electrolytes (ACEs). Discovered serendipitously as derivatives of compounds designed for use in microbial bioelectronics, ACEs evade resistance, destroy biofilms, and selectively target bacteria. Xiretsa is dedicated to tailoring the ACE platform to combat AMR and address the greatest Gram-negative, Gram-positive, and Mycobacterial threats.
Centauri Therapeutics
Centauri Therapeutics is an immunotherapy company, with a unique and proprietary platform technology applicable across a wide range of therapeutic indications. The Company’s initial focus is on infectious diseases, driven by an urgent unmet need for anti-infectives to treat the most vulnerable and at-risk patients. Centauri also has strong initial proof-of-concept data in oncology.
Centauri’s Alphamer® platform has a unique mechanism of action, utilising an antibody recruiting molecule to harness the body’s natural immune response, and redirect antibodies to target diseases.
